Serum miR-599 Serves as a Biomarker for Ischemic Stroke Patients

Sun, Xiaogang; Lv, Junling; Chen, Di; Hu, Xin

doi:10.7754/clin.lab.2019.181256

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, investigating circulating miRNA levels in ischemic stroke patients compared with healthy controls showed downregulation and selective upregulation of certain miRNAs in other types of ischemic stroke [ 41 ]. In addition, selective exosomal miRNAs were shown to be significantly increased in ischemic stroke, with some miRNAs showing potentials of differentiating between early acute phase and recovery phase [ 42 , 43 ], while elevated serum expression levels of certain miRNAs showed correlation with high sensitivity C-reactive protein (hs-CRP) and MMP-9 in ischemic stroke patients [ 44 ]. In addition, some miRNAs have been reported to potentially differentiate between ischemic stroke and TIA patients [ 45 ].…”

Section: Discussionmentioning

confidence: 99%

Identification of Novel Circulating miRNAs in Patients with Acute Ischemic Stroke

Al-Dous

Toor

Parray

et al. 2022

IJMS

View full text Add to dashboard Cite

Ischemic strokes are associated with significant morbidity and mortality, but currently there are no reliable prognostic or diagnostic blood biomarkers. MicroRNAs (miRNAs) regulate various molecular pathways and may be used as biomarkers. Using RNA-Seq, we conducted comprehensive circulating miRNA profiling in patients with ischemic stroke compared with healthy controls. Samples were collected within 24 h of clinical diagnosis. Stringent analysis criteria of discovery (46 cases and 95 controls) and validation (47 cases and 96 controls) cohorts led to the identification of 10 differentially regulated miRNAs, including 5 novel miRNAs, with potential diagnostic significance. Hsa-miR-451a was the most significantly upregulated miRNA (FC; 4.8, FDR; 3.78 × 10−85), while downregulated miRNAs included hsa-miR-574-5p and hsa-miR-142-3p, among others. Importantly, we computed a multivariate classifier based on the identified miRNA panel to differentiate between ischemic stroke patients and healthy controls, which showed remarkably high sensitivity (0.94) and specificity (0.99). The area under the ROC curve was 0.97 and it is superior to other current available biomarkers. Moreover, in samples collected one month following stroke, we found sustained upregulation of hsa-miR-451a and downregulation of another 5 miRNAs. Lastly, we report 3 miRNAs that were significantly associated with poor clinical outcomes of stroke, as defined by the modified Rankin scores. The clinical translation of the identified miRNA panel may be explored further.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of Novel Circulating miRNAs in Patients with Acute Ischemic Stroke

Al-Dous

Toor

Parray

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Besides, miRNAs can be used as disease biomarkers and therapeutic targets due to their stability and conservatism in blood. MiR-3352 [ 11 ], miR-451 [ 12 ], miR-599 [ 13 ] can be used as potential biomarkers of CAS. Among a variety of miRNAs, miR-637 is located on chromosome 19p13.3, and its effect on hepatoma [ 14 ], cholangiocarcinoma [ 15 ], gastric cancer [ 16 ], melanoma [ 17 ], and other diseases have been confirmed.…”

Section: Introductionmentioning

confidence: 99%

Dysregulation of miR-637 serves as a diagnostic biomarker in patients with carotid artery stenosis and predicts the occurrence of the cerebral ischemic event

Zhang

Liu

2021

Bioengineered

View full text Add to dashboard Cite

show abstract

“…8,9 Many miRNAs have been identified to be aberrantly expressed in human carotid plaques, such as miR-100, miR-125a, and miR-127, suggesting their potential regulator role in the development of CAS. 10 Moreover, miRNAs seem to play a crucial role in the etiology and pathology of IS, and circulating miRNAs have been regarded to be both potential biomarkers and mediators of CIE. 11,12 Wang et al have reported that miR-106b-5p is aberrantly expressed in acute stroke patients, and it might be a novel biomarker for the early detection of acute stroke. 13 The latest research on the coexpression pattern of miRNAs in plasma of patients with atherosclerosis has also suggested that miR-106b-5p shows the most significant difference and plays an important role in the regulatory network of atherosclerotic gene expression, revealing its crucial role in atherosclerosis.…”

Section: Introductionmentioning

confidence: 99%

Circulating miR-106b-5p serves as a diagnostic biomarker for asymptomatic carotid artery stenosis and predicts the occurrence of cerebral ischemic events

et al. 2020

View full text Add to dashboard Cite

This study aimed to investigate the expression and diagnostic value of miR-106b-5p in asymptomatic carotid artery stenosis (CAS) patients, and further explore its predictive value for the occurrence of cerebral ischemic events (CIE). A total of 58 asymptomatic CAS cases and 61 healthy controls were recruited. Quantitative RT-PCR was applied for the measurement of the miR-106b-5p level. The receiver operating characteristic (ROC) curve was plotted to assess the diagnostic value of miR-106b-5p for CAS. Kaplan–Meier methods and Cox regression analysis were performed to assess the predictive value of miR-106b-5p for the occurrence of CIE. In patients with asymptomatic CAS, miR-106b-5p was highly expressed. The miR-106b-5p level showed a significant association with dyslipidemia, hypertension, and the degree of carotid stenosis. miR-106b-5p had a relative accuracy in differentiating patients with asymptomatic CAS from healthy individuals, with a sensitivity of 89.7% and specificity of 83.6% at the cutoff value of 0.198. Patients with high miR-106b-5p expression experienced more CIE. miR-106b-5p was highly expressed in patients with asymptomatic CAS. Our present results provide evidence for miR-106b-5p as a promising biomarker for CAS diagnosis, and for predicting the risk of future CIE in patients with asymptomatic CAS.

show abstract

Serum miR-599 Serves as a Biomarker for Ischemic Stroke Patients

Cited by 3 publications

References 0 publications

Identification of Novel Circulating miRNAs in Patients with Acute Ischemic Stroke

Identification of Novel Circulating miRNAs in Patients with Acute Ischemic Stroke

Dysregulation of miR-637 serves as a diagnostic biomarker in patients with carotid artery stenosis and predicts the occurrence of the cerebral ischemic event

Circulating miR-106b-5p serves as a diagnostic biomarker for asymptomatic carotid artery stenosis and predicts the occurrence of cerebral ischemic events

Contact Info

Product

Resources

About